Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Adjuvant T-DM1 bij stadium I HER2-positieve borstkanker: resultaten na 5 jaar
nov 2024 | Borstkanker